title: Do selective serotonin receptor inhibitor antidepressants reduce tamoxifen's effectiveness and increase the risk of death from breast cancer?
authors.affiliation: Sunnybrook Odette Cancer Centre, Toronto, Ontario M4N 3M5 Canada. Kathy.Pritchard@sunnybrook.ca
authors.forename: Kathleen I
authors.initials: KI
authors.lastname: Pritchard
mesh_terms: D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects*; D018931:Antineoplastic Agents, Hormonal / Q000378:metabolism* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality*; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics / Q000378:metabolism; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D004347:Drug Interactions; D005260:Female; D006801:Humans; D011960:Receptors, Estrogen / Q000032:analysis; D012702:Serotonin Antagonists / Q000009:adverse effects*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D013629:Tamoxifen / Q000378:metabolism* / Q000627:therapeutic use
chemical_list: D018687:Antidepressive Agents, Second-Generation; D018931:Antineoplastic Agents, Hormonal; D019389:Cytochrome P-450 CYP2D6; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D011960:Receptors, Estrogen; D012702:Serotonin Antagonists; D017367:Selective Serotonin Reuptake Inhibitors; D013629:Tamoxifen